ORAGENICS, INC. Proceeds from (Repayments of) Restricted Cash, Financing Activities
ORAGENICS, INC. (OGEN) reported Proceeds from (Repayments of) Restricted Cash, Financing Activities of -$1.41 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2018-11-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities · last filed 2018-11-13
- ORAGENICS, INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2017-09-30 was $510.92K.
- ORAGENICS, INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- ORAGENICS, INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2013-09-30 was $0.00, a 100.00% decline year-over-year.
- ORAGENICS, INC. proceeds from (repayments of) restricted cash, financing activities for the quarter ending 2013-06-30 was $25.77K, a 73.89% decline year-over-year.
- ORAGENICS, INC. proceeds from (repayments of) restricted cash, financing activities for fiscal 2013 was $61.76K, a 69.60% decline from fiscal 2012.
- ORAGENICS, INC. proceeds from (repayments of) restricted cash, financing activities for fiscal 2012 was $203.20K, a 3.56% decline from fiscal 2011.
- ORAGENICS, INC. proceeds from (repayments of) restricted cash, financing activities for fiscal 2011 was $210.70K, a 89.33% decline from fiscal 2010.
- ORAGENICS, INC. proceeds from (repayments of) restricted cash, financing activities for fiscal 2010 was $1.97M.
| Period end | Proceeds from (Repayments of) Restricted Cash, Financing Activities 3 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 6 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 9 month | Proceeds from (Repayments of) Restricted Cash, Financing Activities 12 month |
|---|---|---|---|---|
| 2017-09-30 | $510.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$1.41M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | -$1.92M 10-Q · filed 2018-08-13 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $0.00 derived: sum of 2 quarters · filed 2015-02-27 | $25.77K derived: sum of 3 quarters · filed 2015-02-27 | $61.76K 10-K · filed 2015-02-27 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-03 | $25.77K derived: sum of 2 quarters · filed 2014-11-03 | $61.76K 10-Q · filed 2014-11-03 | $144.59K derived: sum of 4 quarters · filed 2014-11-03 |
| 2013-06-30 | $25.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $61.76K 10-Q · filed 2014-08-07 | $144.59K derived: sum of 3 quarters · filed 2014-08-07 | $195.39K derived: sum of 4 quarters · filed 2014-08-07 |
| 2013-03-31 | $35.99K 10-Q · filed 2014-05-09 | $118.81K derived: sum of 2 quarters · filed 2014-05-09 | $169.62K derived: sum of 3 quarters · filed 2014-05-09 | $268.33K derived: sum of 4 quarters · filed 2014-05-09 |
| 2012-12-31 | $82.82K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $133.63K derived: sum of 2 quarters · filed 2014-02-28 | $232.34K derived: sum of 3 quarters · filed 2014-02-28 | $203.20K 10-K · filed 2014-02-28 |
| 2012-09-30 | $50.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-25 | $149.52K derived: sum of 2 quarters · filed 2013-10-25 | $120.37K 10-Q · filed 2013-10-25 | $238.34K derived: sum of 4 quarters · filed 2013-10-25 |
| 2012-06-30 | $98.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | $69.57K 10-Q · filed 2013-08-12 | $187.53K derived: sum of 3 quarters · filed 2013-08-12 | $245.37K derived: sum of 4 quarters · filed 2013-08-12 |
| 2012-03-31 | -$29.14K 10-Q · filed 2013-05-15 | $88.82K derived: sum of 2 quarters · filed 2013-05-15 | $146.66K derived: sum of 3 quarters · filed 2013-05-15 | $94.68K derived: sum of 4 quarters · filed 2013-05-15 |
| 2011-12-31 | $117.96K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-26 | $175.80K derived: sum of 2 quarters · filed 2013-03-26 | $123.82K derived: sum of 3 quarters · filed 2013-03-26 | $210.70K 10-K · filed 2013-03-26 |
| 2011-09-30 | $57.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | $5.86K derived: sum of 2 quarters · filed 2012-11-14 | $92.73K 10-Q · filed 2012-11-14 | $172.22K derived: sum of 4 quarters · filed 2012-11-14 |
| 2011-06-30 | -$51.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-10 | $34.90K 10-Q · filed 2012-08-10 | $114.39K derived: sum of 3 quarters · filed 2012-08-10 | $301.92K derived: sum of 4 quarters · filed 2012-08-10 |
| 2011-03-31 | $86.88K 10-Q · filed 2012-05-15 | $166.37K derived: sum of 2 quarters · filed 2012-05-15 | $353.90K derived: sum of 3 quarters · filed 2012-05-15 | |
| 2010-12-31 | $79.49K derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | $267.02K derived: sum of 2 quarters · filed 2012-04-16 | $1.97M 10-K · filed 2012-04-16 | |
| 2010-09-30 | $187.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $1.89M 10-Q · filed 2011-11-14 | ||
| 2010-06-30 | $1.71M 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |